The effect of repeat administration of GTS-21 on mixed-function oxidase activities in rat

Toxicology Letters

Volumn 110, Issue 3, 1999, Pages 137-144

  Azuma, Ryotaro ^a   Komuro, Masahito ^a   Black, Sherry R ^b   Mathews, James M ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b RTI INTERNATIONAL   (United States)

Author keywords

Cytochrome P450; Enzyme activity; GTS 21; Induction; Phenobarbital

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; OXIDOREDUCTASE; UNSPECIFIC MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ANALYSIS; LIVER FUNCTION; LIVER TOXICITY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ALZHEIMER DISEASE; ANIMALS; BENZYLIDENE COMPOUNDS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; ISOENZYMES; MALE; MIXED FUNCTION OXYGENASES; NICOTINIC AGONISTS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

ANIMALIA;

EID: 0032747427     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(99)00150-2     Document Type: Article

References (21)

1. Azuma, R., Komuro, M., Korsch, B.H., Andre, J.C., Onnagawa, O., Black, S.R., Mathews, J.M., 1999. Metabolism and disposition of GTS-21, a novel drug for Alzheimer's disease. Xenobiotica 29, 747-762.
2. Bochner F., Somogyi A.A., Chen Z.R. Dextromethorphan metabolism in rat: interstrain differences and the fate of individually administered oxidative metabolites. Xenobiotica. 24:1994;543-552.
3. Cribb A.E., Spielberg S.P., Griffin G.P. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab. Dispos. 23:1995;406-414.
4. Guengerich F.P., Hosea N.A., Parikh A., Bell-Parikh L.C., Johnson W.W., Gillam E.M., Shimada T. Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs. Drug Metab. Dispos. 26:1998;1175-1178.
5. Kerry N.L., Somogyi A.A., Mikus G., Bochner F. Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes. Biochem. Pharmacol. 45:1993;833-839.
6. Kitagawa H., Moriyama A., Takenouchi T., Wesnes K., Kramer W., Clody D.E. Phase I studies of GTS-21 to assess the safety, tolerability, PK and effects on measures of cognitive function in normal volunteers. Neurobiol. Aging. 19(Suppl 2):1998;S182.
7. Koop D.R., Laethem C.L., Tierney D.J. The utility of p-nitrophenol hydroxylation in P450IIE1 analysis. Drug Metab. Rev. 20:1989;541-551.
8. Liu G., Gelboin H.V., Myers M.J. Role of cytochrome P450 1A2 in acetanilide 4-hydroxylation as determined with cDNA expression and monoclonal antibodies. Arch. Biochem. Biophys. 284:1991;400-406.
9. Mathews, J.M., Raymer, J.H., Velez, G.R., Garner, C.E., Bucher, J.R., 1996. The influence of cytochrome P450 enzyme activity on the composition and quantity of volatile organics in expired breath. Biomarkers 1, 196-201.
10. Meyer E.M., King M.A., Meyers C. Neuroprotective effects of 2,4-dimethoxybenzylidene anabaseine (DMXB) and tetrahydroaminoacridine (THA) in neocortices of nucleus basalis lesioned rats. Brain Res. 786:1998;252-254.
11. Nanri M., Yamamoto J., Miyake H., Watanabe H. Protective effect of GTS-21, a novel nicotinic receptor agonist, on delayed neuronal death induced by ischemia in gerbils. Jpn. J. Pharmacol. 76:1998a;23-29.
12. Nanri M., Miyake H., Murakami Y., Matsumoto K., Watanabe H. GTS-21, a nicotinic agonist, attenuates multiple infarctions and cognitive deficit caused by permanent occlusion of bilateral common carotid arteries in rats. Jpn. J. Pharmacol. 78:1998b;463-469.
13. Omura T., Sato R. The carbon monoxide binding pigment of liver microsomes I. Evidence for its hemoprotein nature. J. Biol. Chem. 239:1964;2370-2378.
14. Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol. Pathol. 24:1996;45-57.
15. Reinke L.A., Moyer M.J. p-Nitrophenol hydroxylation. A microsomal oxidation which is highly inducible by ethanol. Drug Metab. Dispos. 13:1985;548-552.
16. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:1994;414-423.
17. Smith D.A., Abel S.M., Hyland R., Jones B.C. Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica. 28:1998;1095-1128.
18. Soucek P., Gut I. Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica. 22:1992;83-103.
19. Stevens K.E., Kem W.R., Mahnir V.M., Freedman R. Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology. 136:1998;320-327.
20. Whitlock J.P. Jr., Denison M.S. Induction of cytochrome P450 enzymes that metabolize xenobiotics. Ortiz de Montellano P.R. Cytochrome P450: Structure, Mechanism, and Biochemistry. 1995;367-390 Plenum Press, New York.
21. Zhang X.J., Thomas P.E. Erythromycin as a specific substrate for cytochrome P4503A isozymes and identification of a high-affinity erythromycin N-demethylase in adult female rats. Drug Metab. Dispos. 24:1996;23-27.